Bubendorf/Basel, March 20, 2015 – Bachem Group (SIX: BANB), the technology leader in the field of peptide chemistry with a focus on quality and innovation, performed well in fiscal year 2014. The Group generated sales of 183.9 million CHF (2013: 170.7 million CHF, +7.8% in CHF and +7.9% in local currency/LC). Thanks to targeted cost-savings and further efficiency gains, operating profit (EBIT) increased by 21.8% to 35.9 million CHF. This figure includes a gain of 2.0 million CHF on the divestment of the non-core immunology product line. The EBITDA margin amounted to 29.9%, the EBIT margin was 19.5%. Net income rose by 23.1% to 29.1 million CHF. Bachem thus met its communicated sales targets in full amid an ongoing competitive market environment and grew its net income at a proportionally much faster rate after already reporting a 51.7% increase in net income for the previous fiscal year.
Fiscal year 2014: Renewed sales growth and sharply higher profits
March 20, 2015
test theme builder local clear 256mb